These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 31488371)

  • 21. Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit.
    Parkash R; Sapp JL; Basta M; Doucette S; Thompson K; Gardner M; Gray C; Brownell B; Kidwai H; Cox J
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):706-13. PubMed ID: 22685111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microvolt T-wave alternans identifies patients with ischemic cardiomyopathy who benefit from implantable cardioverter-defibrillator therapy.
    Chow T; Kereiakes DJ; Bartone C; Booth T; Schloss EJ; Waller T; Chung E; Menon S; Nallamothu BK; Chan PS
    J Am Coll Cardiol; 2007 Jan; 49(1):50-8. PubMed ID: 17207722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cluster Randomized Trial Examining the Impact of Automated Best Practice Alert on Rates of Implantable Defibrillator Therapy.
    Lee J; Szeto L; Pasupula DK; Hussain A; Waheed A; Adhikari S; Sharbaugh M; Thoma F; Althouse AD; Fischer G; Lee JS; Saba S
    Circ Cardiovasc Qual Outcomes; 2019 Jun; 12(6):e005024. PubMed ID: 31181957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implantable cardioverter-defibrillator therapy among patients with non-ischaemic vs. ischaemic cardiomyopathy for primary prevention of sudden cardiac death.
    Amara N; Boveda S; Defaye P; Klug D; Treguer F; Amet D; Perier MC; Gras D; Algalarrondo V; Bouzeman A; Piot O; Deharo JC; Fauchier L; Babuty D; Bordachar P; Sadoul N; Marijon E; Leclercq C;
    Europace; 2018 Jan; 20(1):65-72. PubMed ID: 28082419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of revascularization on mortality and risk of ventricular arrhythmia in patients with ischemic cardiomyopathy.
    Alkharaza A; Al-Harbi M; El-Sokkari I; Doucette S; MacIntyre C; Gray C; Abdelwahab A; Sapp JL; Gardner M; Parkash R
    BMC Cardiovasc Disord; 2020 Oct; 20(1):455. PubMed ID: 33087069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positron emission tomography absolute stress myocardial blood flow for risk stratification in nonischemic cardiomyopathy.
    Middour TG; Rosenthal TM; Abi-Samra FM; Bernard ML; Khatib S; Polin GM; Rogers PA; Bober RM; Morin DP
    J Cardiovasc Electrophysiol; 2020 May; 31(5):1137-1146. PubMed ID: 32064730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators.
    Bilchick KC; Wang Y; Cheng A; Curtis JP; Dharmarajan K; Stukenborg GJ; Shadman R; Anand I; Lund LH; Dahlström U; Sartipy U; Maggioni A; Swedberg K; O'Conner C; Levy WC
    J Am Coll Cardiol; 2017 May; 69(21):2606-2618. PubMed ID: 28545633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis.
    Beggs SAS; Jhund PS; Jackson CE; McMurray JJV; Gardner RS
    Heart; 2018 Jan; 104(2):144-150. PubMed ID: 28986406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early mortality in prophylactic implantable cardioverter-defibrillator recipients: development and validation of a clinical risk score.
    Kraaier K; Scholten MF; Tijssen JG; Theuns DA; Jordaens LJ; Wilde AA; van Dessel PF
    Europace; 2014 Jan; 16(1):40-6. PubMed ID: 23918791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ICD risk stratification studies - EU-CERT-ICD and the European perspective.
    Seegers J; Bergau L; Tichelbäcker T; Malik M; Zabel M
    J Electrocardiol; 2016; 49(6):831-836. PubMed ID: 27623399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylactic implantation of cardioverter defibrillators in idiopathic nonischemic cardiomyopathy for the primary prevention of death: a narrative review.
    Cevik C; Nugent K; Perez-Verdia A; Fish RD
    Clin Cardiol; 2010 May; 33(5):254-60. PubMed ID: 20513063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE).
    Healey JS; Hohnloser SH; Glikson M; Neuzner J; Mabo P; Vinolas X; Kautzner J; O'Hara G; VanErven L; Gadler F; Pogue J; Appl U; Gilkerson J; Pochet T; Stein KM; Merkely B; Chrolavicius S; Meeks B; Foldesi C; Thibault B; Connolly SJ;
    Lancet; 2015 Feb; 385(9970):785-91. PubMed ID: 25715991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implantable Cardioverter Defibrillator for the Primary Prevention of Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy.
    Cavalcanti R; Aboul-Hosn N; Morales G; Abdel-Latif A
    Angiology; 2018 Apr; 69(4):297-302. PubMed ID: 28554215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peri-procedural routines, implantation techniques, and procedure-related complications in patients undergoing implantation of subcutaneous or transvenous automatic cardioverter-defibrillators: results of the European Snapshot Survey on S-ICD Implantation (ESSS-SICDI).
    Lenarczyk R; Boveda S; Haugaa KH; Potpara TS; Syska P; Jedrzejczyk-Patej E; Chauvin M; Sadoul N; Dagres N
    Europace; 2018 Jul; 20(7):1218-1224. PubMed ID: 29762683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis.
    Theuns DA; Smith T; Hunink MG; Bardy GH; Jordaens L
    Europace; 2010 Nov; 12(11):1564-70. PubMed ID: 20974768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy.
    Pathak RK; Sanders P; Deo R
    Eur Heart J; 2018 Aug; 39(31):2859-2866. PubMed ID: 30020440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit: Insights From the DANISH Trial.
    Kristensen SL; Levy WC; Shadman R; Nielsen JC; Haarbo J; Videbæk L; Bruun NE; Eiskjær H; Wiggers H; Brandes A; Thøgersen AM; Hassager C; Svendsen JH; Høfsten DE; Torp-Pedersen C; Pehrson S; Signorovitch J; Køber L; Thune JJ
    JACC Heart Fail; 2019 Aug; 7(8):717-724. PubMed ID: 31302052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening and risk evaluation for sudden cardiac death in ischaemic and non-ischaemic cardiomyopathy: results of the European Heart Rhythm Association survey.
    Proclemer A; Lewalter T; Bongiorni MG; Svendsen JH; Pison L; Lundqvist CB;
    Europace; 2013 Jul; 15(7):1059-62. PubMed ID: 23794672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.